Sign In
Buy PDCO
$31.33
+0 (+0%)
At Close: Jul 16, 2025
What's in Store for Patterson Companies (PDCO) in Q1 Earnings?
12:47pm, Monday, 29'th Aug 2022
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.
Here's Why Investors Should Retain Myriad Genetics (MYGN) Now
05:15pm, Friday, 26'th Aug 2022 Zacks Investment Research
Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
12:50pm, Friday, 26'th Aug 2022 Zacks Investment Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
5 Cheap Healthcare Stocks in 2022
05:45pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?
Fresenius Medical (FMS) Robust Product Portfolio Drives Growth
04:07pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
03:57pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Analysts Estimate Patterson Cos. (PDCO) to Report a Decline in Earnings: What to Look Out for
02:00pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patterson Companies Fiscal 2023 First Quarter Conference Call Scheduled for Thursday, September 1, 2022
06:30pm, Wednesday, 24'th Aug 2022
ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies (Nasdaq: PDCO) today announced that it will hold its fiscal 2023 first-quarter earnings conference call on Thursday, September 1, 2022 at 7:30 a.m
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
06:04pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Abbott (ABT) to Offer New Treatment Option for Chronic Pain
04:32pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.
Here's Why You Should Retain Exact Sciences (EXAS) Now
04:22pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
03:15pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
02:30pm, Tuesday, 23'rd Aug 2022 Zacks Investment Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
02:22pm, Tuesday, 23'rd Aug 2022 Zacks Investment Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
04:56pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.
